Micro Pharmaceuticals
Market Cap
₹1,861 ₹1,861 Cr.
P/E
13.67
PEG
1.23
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The thesis comes alive with poultry expansion, H9N2 commercialization and recovery in Animal Healthcare tenders and immunisation programs.

The bull path requires H9N2 commercialization alongside tender recovery, while the bear path reflects delayed tenders, weaker poultry revenue, underused capacity and margin pressure.

Key Ratios

Debt to Equity
Debt to Equity
0.52
Div Yield (%)
Div Yield (%)
0.50
Individual < 2 lac
Individual < 2 lac
18.42 %
Institutions
Institutions
0.31 %
Market cap
Market cap
1,861 Cr
No. of Shareholders
No. of Shareholders
11,961
OPM (%)
OPM (%)
26.59 %
PE
PE
13.67
Prom Holding
Prom Holding
53.73 %
ROCE (%)
ROCE (%)
14.74
ROE (%)
ROE (%)
15.45
Sales
Sales
325 Cr
  • Hester Biosciences
  • NGL Fine-Chem
  • Kopran
  • TJI Pharma - Small Cap
Last updated on 6 Oct 2026
  • Hester Biosciences makes poultry and animal-health vaccines. Poultry is ~85% of standalone revenue. Buyers are commercial poultry farms and government immunisation programmes.
  • International sales are ~6% of consolidated revenue. The range covers avian influenza, Peste des Petits Ruminants, lumpy skin disease and goat pox vaccines, with a Brucella recombinant vaccine in R&D.
  • Poultry grew 48% year on year in Q1FY27 on share gains and the new H9N2 avian influenza vaccine. Animal healthcare halved as government tenders slipped.
  • Per management, one sales network cross-sells animal-health products into the poultry channel. A biosafety level 3 high-containment block, repurposed from a COVID programme, is in service.
  • Q1FY27 EBITDA margin reached 36%, versus ~30% in FY26 and 21% a year earlier. The jump came from product mix and ~65% utilisation, not pricing.
  • Hester Africa, the Kenya vaccine manufacturing subsidiary, is still pre-profit. A Gates Foundation loan was restructured interest-free, with a tax holiday till 2030.
  • Near-term earnings depend on the EBITDA margin holding above 30% and on animal-health tender recovery materialising in H2FY27, as management expects.
  • The promoter group is falling from ~53.7% to ~44.3%. Ravin Gandhi and Bela Gandhi, holding ~9.4%, reclassified to public shareholders in September 2026.
  • CARE upgraded the credit rating to BBB+/Stable in August 2026, citing lower debt and a reduced rated bank line.
  • First post-reclassification shareholding pattern early Oct 2026
    It confirms the promoter group at ~44.3% and shows any bulk sell-down by the reclassified members.
  • Q2FY27 print ~late Oct–Nov 2026
    Shows whether the 36% EBITDA margin holds above 30% and whether animal health recovers as management claims.
  • PPR and lumpy skin disease government tenders H2FY27
    Tender orders restore the animal-health segment, which halved when the government programmes slipped.
  • Group captive solar investment by ~Apr 2027
    Completes the board-approved ₹1.05Cr payment for 26% of the Slyce Agri World solar LLP and activates its power purchase agreement.
  • Hester Africa breakeven no stated timeline
    The Kenya vaccine manufacturing unit remains loss-making, and management has guided no breakeven date.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
1251
52W Range
High
2669
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

11 Yes

Positive for this company

1 Neutral

Neutral for this company

4 No

Negative for this company

1 No Data

Insufficient data to analyse

Market Share

35 %
(as of Jun 26)
Poultry Vaccines - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Distribution Channel

Operating Profit Break-Up

Capex

Asset Break-Up - Segment

Operational Metrics

    Select a Metric
    • R&D as a % of Total Sales (%)

    Peer Comparison

    Corporate Actions

    Consolidated
    DATE
    DETAILS
    Show More
    Show Less
    Show More
    Show Less

    FAQs on Hester Biosciences Ltd. Business

    Hester Biosciences Limited, a premier animal healthcare company in India known for poultry vaccines. Established in 1987, it has become a top global manufacturer with Asia's largest animal biological manufacturing unit in Ahmedabad.

    Hester Biosciences major competitors are NGL Fine-Chem, Kopran, Bajaj Healthcare, Themis Medicare, Shree Ganesh Remed., Haleos Labs, Everest Organics.
    Market Cap of Hester Biosciences is ₹1,821 Crs.
    While the median market cap of its peers are ₹1,051 Crs.

    Hester Biosciences seems to be financially stable compared to its competitors.
    The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.

    Company Filing

    Discussions & Analysis

    Ideas Dashboard
    Results
    Timeline
    Watchlist
    Portfolio
    Alerts
    Stock Screener
    Market
    Raw Material